Dosing down with biologic therapies: a systematic review and clinicians' perspective.

Item

http://www.wikidata.org/entity/Q39198863

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@en

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@nl

type

Item

label

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@en

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@nl

prefLabel

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@en

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@nl

P1476

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

@en

P2093

Christopher J Edwards

http://www.w3.org/2001/XMLSchema#string

Hendrik Schulze-Koops

http://www.w3.org/2001/XMLSchema#string

Klaus Kruger

http://www.w3.org/2001/XMLSchema#string

Tom W J Huizinga

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

P304

1847-1856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1093/RHEUMATOLOGY/KEW464

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bruno Fautrel

P5008

ScienceSource

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28339632

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

psoriatic arthritis

P932

5850865

http://www.w3.org/2001/XMLSchema#string